25.01.2019 • NewsElaine BurridgeRosneft

Nayara Energy Plans Propylene-PP Complex

Nayara Energy Plans Propylene-PP Complex (c) Nayara Energy
Nayara Energy Plans Propylene-PP Complex (c) Nayara Energy

India’s Nayara Energy, owned 49.13% by Russian oil giant Rosneft, is planning to invest $850 million to expand its Vadinar refinery in Gujarat and build a petrochemical complex.

A first phase would see the construction of a 450,000 t/y propylene recovery facility, a 450,000 t/y PP plant and a 200,000 t/y methyl tertiary-butyl ether (MTBE) unit. The company is currently carrying out an economic evaluation of the project and a final decision to proceed will be made during 2019.

“The planned investment is basically a diversification into the petrochemical business,” explained Nayara’s CEO B Anand, adding that the complex is scheduled for completion in 2022.

Global trading group Trafigura and Russia’s UCP Investment together also own 49.13% of Nayara Energy, which was formerly known as Essar Oil. Rosneft together with a consortium led by Trafigura and UCP acquired the company from Essar Energy Holdings and its affiliates in August 2017, paying $12.9 billion.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.